Isofol Medical AB, a small Swedish company founded a decade ago, is seeking to improve the standard of care (SOC) for metastatic colorectal cancer (mCRC), an oncology indication that receives far less attention than metastatic forms of more prevalent breast, prostate and lung cancers, said CEO Anders Rabbe. The Gothenburg-based company disclosed results from the open-label extension of its phase I/IIa study of folate receptor antagonist arfolitixorin (Modufolin) in individuals with mCRC that underpin a phase III effort that was initiated last month.